FORA Capital LLC Acquires Shares of 16,752 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

FORA Capital LLC bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 16,752 shares of the company’s stock, valued at approximately $1,930,000.

Several other institutional investors also recently modified their holdings of the business. Public Employees Retirement System of Ohio increased its position in Neurocrine Biosciences by 6.6% during the 1st quarter. Public Employees Retirement System of Ohio now owns 47,947 shares of the company’s stock valued at $6,613,000 after buying an additional 2,987 shares in the last quarter. Tidal Investments LLC increased its holdings in shares of Neurocrine Biosciences by 57.8% during the first quarter. Tidal Investments LLC now owns 9,542 shares of the company’s stock valued at $1,316,000 after acquiring an additional 3,497 shares in the last quarter. LBP AM SA purchased a new position in shares of Neurocrine Biosciences in the 1st quarter worth about $910,000. Plato Investment Management Ltd bought a new position in Neurocrine Biosciences in the 1st quarter worth about $41,000. Finally, New Covenant Trust Company N.A. bought a new position in Neurocrine Biosciences in the 1st quarter worth about $32,000. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences Stock Down 1.0 %

NASDAQ NBIX opened at $126.59 on Thursday. Neurocrine Biosciences, Inc. has a twelve month low of $110.81 and a twelve month high of $157.98. The business has a 50-day moving average price of $118.97 and a 200-day moving average price of $131.71. The firm has a market cap of $12.82 billion, a price-to-earnings ratio of 33.94 and a beta of 0.35.

Analyst Ratings Changes

NBIX has been the subject of a number of analyst reports. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. Jefferies Financial Group boosted their price objective on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the company a “buy” rating in a report on Monday, August 19th. Oppenheimer increased their price objective on shares of Neurocrine Biosciences from $216.00 to $219.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a research report on Monday, September 16th. Finally, Robert W. Baird increased their price target on Neurocrine Biosciences from $157.00 to $180.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Five analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $163.91.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.